Skip to main content
. 2023 Jul 21;25:123. doi: 10.1186/s13075-023-03099-3

Table 2.

Characteristics in anti-CarP isotype positive and negative SSc patients

IgG+
N = 15
IgG-
N = 179
IgM+
N = 36
IgM-
N = 158
IgA+
N = 16
IgA-
N = 178
Female, n (%) 13 (87) 142 (80) 31 (86) 124 (79) 10 (63) 145 (82)
Age (years), mean (SD) 52 (16) 55 (13) 55 (15) 55 (13) 57 (10) 55 (14)
Disease duration since non-RP (months), median (IQR) 92 (40; 160) 43 (22; 122) 46 (22; 98) 45 (23; 136) 45 (20; 70) 46 (24; 138)
Disease duration since RP, (months), median (IQR) 116 (61; 239) 98 (45; 232) 85 (40; 223) 112 (48; 239) 64 (32; 163) 110 (48; 232)
Anti-topoisomerase antibodies, n (%) 5 (33) 39 (22) 11 (31) 33 (22) 7 (44) 37 (21)
Anti-centromere antibodies, n (%) 5 (33) 75 (43) 18 (50) 62 (40) 5 (31) 75 (43)
Modified Rodnan Skin Score, median (IQR) 7 (0; 10) 2 (0; 6) 2 (0; 6) 3 (1; 8) 3 (0; 6) 2 (0; 6)
Disease subset, n (%)
 • Non cutaneous 2 (6) 34 (94) 6 (17) 30 (83) 3 (8) 33 (92)
 • Limited cutaneous 8 (7) 111 (93) 22 (19) 97 (82) 9 (8) 110 (92)
 • Diffuse cutaneous 5 (13) 34 (87) 8 (21) 31 (80) 4 (10) 35 (90)
Synovitis, n (%) 1 (7) 11 (6) 3 (8) 9 (6) 1 (6) 11 (6)

Anti-CarP anti-carbamylated protein antibodies, SSc systemic sclerosis, N number, SD standard deviation, IQR interquartile range